INHIBRX BIOSCIENCES, INC. (INBX) FY2026 Q2 Balance Sheet

INHIBRX BIOSCIENCES, INC. (INBX) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets

154,222,000 US dollars

Current assets

142,212,000 US dollars

Non-current assets

12,010,000 US dollars

Liabilities

207,199,000 US dollars

Current liabilities

28,064,000 US dollars

Non-current liabilities

179,135,000 US dollars

Equity

negative 52,977,000 US dollars

Cash and cash equivalents

133,344,000 US dollars

Prepaid expenses and other current assets

8,736,000 US dollars

Other receivables

132,000 US dollars

Other non-current assets

4,769,000 US dollars

Operating right-of-use asset

4,555,000 US dollars

Property and equipment, net

2,686,000 US dollars

Accrued expenses

15,773,000 US dollars

Accounts payable

9,800,000 US dollars

Current portion of operating lease liability

2,491,000 US dollars

Long-term debt, net

176,285,000 US dollars

Non-current portion of operating lease liability

2,850,000 US dollars

Additional paid-in-capital

263,300,000 US dollars

Common stock, $0.0001 par value; 120,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 14,708,910 shares issued and outstanding as of June 30, 2026 and 14,577,609 shares issued and outstanding as of December 31, 2025.

1,000 US dollars

Preferred stock, $0.0001 par value; 15,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued or outstanding as of June 30, 2026 and December 31, 2025.

0 US dollars

Accumulated deficit

negative 316,278,000 US dollars

Chart connections

• Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.